Radiotherapy combined with third-generation EGFR tyrosine kinase inhibitor in first-line treatment of advanced oligometastatic non-small cell lung cancer: a single-center, retrospective study

作者
Jianqingchen Chen,Jia Yao,Qi Cheng,Yu Wang,Zhuojuan Wei,Huan Chen,Lin Wang,Ruiqi Wang,Honglian Ma,Xiao Yan Lin,Yujin Xu
出处
期刊:Journal of Thoracic Disease [AME Publishing Company]
卷期号:18 (1): 25-25
标识
DOI:10.21037/jtd-2025-aw-2030
摘要

Background: Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC). However, disease progression remains inevitable, particularly in the oligometastatic setting. We hypothesized that local radiotherapy (RT) could alter the disease course by eradicating resistant clones. Therefore, this study aimed to evaluate the efficacy of RT combined with a third-generation EGFR-TKI as first-line therapy for advanced oligometastatic NSCLC. Methods: We retrospectively analyzed EGFR-mutant advanced oligometastatic NSCLC patients treated with third-generation EGFR-TKI at Zhejiang Cancer Hospital. Patients were stratified into TKI only group and TKI + RT group. Efficacy and safety were compared across groups. Results: From March 2021 to September 2023, a total of 260 patients were enrolled, including 143 received TKI only group and 117 received TKI + RT group. With the median follow-up of 26.2 months, the median progression-free survival (PFS) was 20.6 and 26.0 months (P=0.18), and the median overall survival (OS) was 45.5 and 52.2 months (P=0.98) for TKI only and TKI + RT group respectively. For the subgroup of delivered biologically effective dose with an α/β ratio of 10 Gy (BED10), BED10 ≥50 Gy group achieved significantly better median PFS than the TKI only group (32.1 vs. 20.6 months; P=0.02), while BED10 <50 Gy group showed no significant improvement compared with TKI only group (22.1 vs. 20.6 months, P=0.61). The median OS had no significant differences for BED10 ≥50 Gy vs. TKI only (P=0.26) and BED10 <50 Gy vs. TKI only (P=0.72). The median PFS in patients with brain metastases was significantly improved with RT (BED10 ≥50 Gy) (37.9 vs. 17.3 months, P=0.02). Multivariate analysis identified female, N0–2 stage, non-smoking, 1–2 metastatic lesions, and RT (BED10 ≥50 Gy) as independent favorable prognostic factors for PFS. Subgroup analysis confirmed significantly improved PFS in patients with brain metastases. RT-related adverse events (AEs) (radiation pneumonitis, esophagitis, and cerebral edema) were all grade ≤2. Conclusions: RT (BED10 ≥50 Gy) combined with third-generation EGFR-TKI therapy improved PFS with favorable safety in EGFR-mutant advanced oligometastatic NSCLC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
ali8ba发布了新的文献求助10
2秒前
科研通AI2S的应助被简朴煜城采纳,获得10
2秒前
2秒前
LSF关注了科研通微信公众号
2秒前
受伤白安发布了新的文献求助10
2秒前
yjx完成签到,获得积分10
2秒前
F_ken完成签到,获得积分10
3秒前
4秒前
wl完成签到,获得积分10
5秒前
啸西风发布了新的文献求助10
5秒前
张二完成签到,获得积分20
5秒前
Jasper的应助被Lumos采纳,获得30
5秒前
5秒前
活泼糜完成签到,获得积分20
6秒前
万能图书馆的应助被信徒采纳,获得10
6秒前
笨笨完成签到,获得积分10
6秒前
wj完成签到,获得积分10
6秒前
娟娟完成签到,获得积分10
7秒前
甜蜜慕凝完成签到,获得积分10
8秒前
多晒太阳发布了新的文献求助10
8秒前
wl发布了新的文献求助10
8秒前
8秒前
付创完成签到,获得积分10
8秒前
9秒前
so完成签到,获得积分10
9秒前
路在脚下完成签到,获得积分10
9秒前
迷路凝芙发布了新的文献求助10
10秒前
852的应助被缥缈不惜采纳,获得10
11秒前
文献一搜就出完成签到,获得积分10
11秒前
残羽仙完成签到,获得积分10
11秒前
zizi发布了新的文献求助10
11秒前
天天向上的应助被kjwu采纳,获得10
11秒前
hahacsw完成签到,获得积分10
12秒前
so发布了新的文献求助10
12秒前
12秒前
cjy200126发布了新的文献求助10
13秒前
14秒前
大学习时代完成签到,获得积分10
14秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182147
求助须知:如何正确求助?哪些是违规求助? 9571790
关于积分的说明 21820037
捐赠科研通 7778601
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479652